The AML group showed statistically lower NGAL levels than the control group, and this finding is similar to the results of a previous study, which measured the NGAL level in BM samples of AML patients.9 In addition, NGAL levels in the AML group were the lowest among those in other disease entities (Figure 1A). This evidence concerns the gene LCN2 and acute myeloid leukemia.